Areas of Expertise:
 

 
Other M.A.Z.E. Labs Sites:
 
Clinical Studies
On page links
Previous Studies

Allergan

Investigator: Phase 3
A Multicenter, Double-Blind, Randomized, Placebo-Controlled,
Parallel-Group Study of the Safety and Efficacy of a Single Treatment of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex Followed by a Treatment with BOTOX® as Applicable in Patients with Idiopathic Overactive Bladder with Urinary Incontinence
PROTOCOL NUMBER: 191622-095-01 7/10-4/11

 

Johnson and Johnson

Investigator:
In vitro study on the effects of vaginal lubricant prototypes when mixed with human semen samples on sperm motility
PROTOCOL NUMBER: KOYNAP00 06 5/09-8/09

 

Graceway Pharmaceuticals

Investigator:
A Phase 3, Randomized, Double-blind. Placebo-controlled, Mulit-center, Efficacy and Safety Study of Imiquimod Creams in the treatment of External Genital Warts.
Protocol   GW01-0801    1/08-8/09

 

QuatRx Pharmaceuticals

Primary Investigator
Efficacy and Safety of Ospemifene in the Treatment of Moderate to Severe Vaginal
Dryness and Vaginal Pain Associated With Sexual Activity, Symptoms of Vulvar and
Vaginal Atrophy (VVA), Associated With Menopause: A 12-Week, Randomized,
Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing Oral Ospemifene
60 mg Daily Dose With Placebo in Postmenopausal Women.
Protocol 15-50821 8/07- 8/09

 

Auxilium Pharmaceutics, Inc.- Hypogonadiasm

Primary Investigator
Observational study to evaluate the effectiveness of Testim 1% in a large sample of hypogonadal men from a variety of “real world” clinical practice settings by assessing sexual function, mood (depression), body mass index, and testosterone levels.
AUX-TG-225 3/08- 8/09

 

Repros Therapeutics Inc.- Secondary Hypogonadism

Primary Investigator
A Randomized, open-label, fixed dose, active-control, multi-center phase IIB s Study to evaluate fertility in men with secondary hypogonadism comparing topical exogenous administration of testosterone and Androxal (Enclomiphene)
ZA-201 6/08- 8/09

 

Biosante Pharmaceuticals- Hypoactive Sexual Desire Disorder

Primary Investigator
A Phase III, randomized, double-blind, placebo-controlled, multi-center study of long-term safety and efficacy of LibiGel for the treatment of hypoactive sexual desire disorder in postmenopausal women.
TEST WOO7 5/08- Present

 

BioSante Pharmaceuticals-Hypoactive Sexual Desire Disorder

Primary Investigator
A Phase III, randomized, double blind, placebo controlled, multi center study of hypoactive sexual desire disorder in surgically menopausal women.
TESTW008 5/08- Present

 

Medicis Pharmaceutical Corporation Spermatogenesis

Primary Investigator
Randomized, Double-Blind, Placebo-Controlled Study to Examine the Effects of Minocycline Extended- Release Tablets on Spermatogenesis in Human Males.
Protocol MP-0104-18 1/07 – 10/08

 

Bristol-Myers Squibb Company Spermatogenesis

Primary Investigator
A Multicenter, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Spermatogenesis in Healthy Male Subjects During Administration of BMS-562086 CN148-014-017 2/07 – 8/08

 

Palatin Technologies, Inc. Female Sexual Dysfunction

Primary Investigator
A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, At-Home Exploratory Study to Evaluate the Efficacy and Safety of Intranasally Administered PT-141 in Subjects with Female Sexual Arousal Disorder. PT-141-2005-53FB 8/06- 8/08

 

Boehringer Ingelheim Pharmaceuticals, Inc. Female Sexual Dysfunction

Primary Investigator
A Twenty Four Week, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Trial of Flibanserin 25 Milligrams Twice Daily and 50 Milligrams Once and Twice Daily in Premenopausal Women With Hypoactive Sexual Desire Disorder in North America.-Protocol 511.70 7/06- 9/08

 

Pfizer, Inc. Sexual Dysfunction

STUDY # 1082 - A randomized, double-blind, placebo-controlled, fixed dose, multi-center study to evaluate the efficacy, safety and toleration of oral sildenafil administered for 12 weeks to post menopausal women who have been diagnosed with female sexual arousal disorder. 10/02 -12/03

STUDY # 1123 - A randomized, double-blind, double dummy, placebo-controlled, fixed dose, multi-center study to evaluate the efficacy, safety and toleration of oral sildenafil citrate administered for 12 weeks to pre-menopausal women who have been diagnosed with female sexual arousal disorder 10/02 - 12/03

STUDY # 1133 An open-label, multi-center extension study to evaluate the safety, toleration and the sustained efficacy of oral sildenafil administered to women who have been diagnosed with female sexual arousal disorder 7/03 - 2/04

STUDY # 1179 A multi-center open label flexible dose study to investigate the use patterns of Viagra  and the ability of investigators to further optimize subject satisfaction with Viagra through customized instruction. 10/03 – 6/04

 

Boehringer Ingelheim Pharmaceuticals, Inc. Female Sexual Dysfunction

STUDY # 100477 version 19 – REALISE – Real Life Safety and Efficacy -A post-marketing (Phase IV) surveillance study of Levitra. 11/03 –1/04

 

Find clinical trials now

For more information please contact us at studies@mazelabs.com.

 

 
  About Us
|
Contact Us
|
Site Map
Copyright © 2001-2014 M.A.Z.E. Laboratories, Inc. All rights reserved